Neuberger Berman Group LLC cut its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 77.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,501 shares of the medical research company's stock after selling 488,473 shares during the quarter. Neuberger Berman Group LLC's holdings in Amgen were worth $36,099,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of AMGN. Vanguard Group Inc. grew its position in Amgen by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock worth $13,741,409,000 after acquiring an additional 339,522 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after acquiring an additional 2,672,975 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Amgen by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after purchasing an additional 352,143 shares during the period. Norges Bank bought a new stake in shares of Amgen in the fourth quarter worth about $1,541,991,000. Finally, Invesco Ltd. grew its stake in shares of Amgen by 7.5% in the fourth quarter. Invesco Ltd. now owns 3,887,248 shares of the medical research company's stock worth $1,013,172,000 after purchasing an additional 270,135 shares during the last quarter. Institutional investors own 76.50% of the company's stock.
Amgen Trading Up 0.5 %
NASDAQ:AMGN traded up $1.38 on Tuesday, hitting $295.30. The stock had a trading volume of 2,592,038 shares, compared to its average volume of 2,777,829. The stock has a market cap of $158.77 billion, a price-to-earnings ratio of 39.11, a PEG ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a fifty day moving average price of $304.05 and a two-hundred day moving average price of $294.91. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.22%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 126.09%.
Insider Buying and Selling
In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. Johnson Rice set a $294.00 price objective on Amgen in a research report on Wednesday, March 5th. Bank of America boosted their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 9th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $314.91.
Check Out Our Latest Report on Amgen
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
